Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises in the divestment of Apprope to publicly listed MAG Interactive
Mandate

Vinge advises in the divestment of Apprope to publicly listed MAG Interactive

December 21, 2020 M&A

Vinge advises the founders of Apprope, a Swedish mobile game developer, in connection with the divestment of the Apprope to MAG Interactive.

Apprope is a Swedish mobile game developer, founded in 2012. The company develops games aimed at a casual audience, with a focus on games within the word category. 55 million players have played Apprope's games and several of their products have ranked high on the US charts. The company is most famous for the word game Word Bubbles, which has in the past six years generated around ten million downloads, had sales of approximately SEK 100 million and reached the top download charts in the word game category in the US on both App Store and Google Play.

Vinge’s team consisted of Daniel Rosvall and Jonas Bergström.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026